Kestra Medical Technologies (NASDAQ:KMTS) Trading Up 10.1% - Time to Buy?

Key Points

• Shares rose 10.1% to $22.475 on Friday, but trading was thin at ~40,446 shares (about an 88% drop from the average daily volume of 335,844).
• Analysts are mixed: MarketBeat shows a consensus rating of Hold with a $27.40 price target (3 Buys, 1 Hold, 1 Sell), while Goldman Sachs cut its target to $17 and BTIG reiterated a $32 buy.
• Kestra reported Q1 EPS of -$0.61 (missed by $0.01) with revenue up 62.7% YoY but a negative net margin of 171.87%; the company shows strong liquidity (quick ratio 7.32) and insiders have sold 45,000 shares in the past 90 days.

Shares of Kestra Medical Technologies, Ltd. (NASDAQ:KMTS - Get Free Report) rose 10.1% during trading on Friday . The company traded as high as $22.70 and last traded at $22.4750. Approximately 40,446 shares were traded during mid-day trading, a decline of 88% from the average daily volume of 335,844 shares. The stock had previously closed at $20.41.

Analyst Ratings Changes

Several brokerages have commented on KMTS. BTIG Research restated a "buy" rating and set a $32.00 price objective on shares of Kestra Medical Technologies in a research note on Tuesday, April 7th. Weiss Ratings reissued a "sell (d-)" rating on shares of Kestra Medical Technologies in a report on Monday, March 23rd. Finally, The Goldman Sachs Group dropped their price objective on shares of Kestra Medical Technologies from $22.00 to $17.00 and set a "neutral" rating for the company in a report on Thursday, April 9th. Three equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Hold" and a consensus price target of $27.40.

Kestra Medical Technologies Trading Up 11.8%

The company's fifty day moving average is $22.23 and its two-hundred day moving average is $24.29. The stock has a market cap of $1.33 billion and a price-to-earnings ratio of -5.76. The company has a quick ratio of 7.32, a current ratio of 7.32 and a debt-to-equity ratio of 0.15.

Kestra Medical Technologies (NASDAQ:KMTS - Get Free Report) last issued its earnings results on Tuesday, March 17th. The company reported ($0.61) earnings per share for the quarter, missing the consensus estimate of ($0.60) by ($0.01). The firm had revenue of $24.55 million during the quarter. Kestra Medical Technologies had a negative net margin of 171.87% and a negative return on equity of 65.49%. The business's revenue was up 62.7% on a year-over-year basis.

Insider Activity

In other news, insider Brian Daniel Webster sold 15,000 shares of the firm's stock in a transaction that occurred on Wednesday, April 15th. The shares were sold at an average price of $20.04, for a total transaction of $300,600.00. Following the transaction, the insider directly owned 349,786 shares in the company, valued at approximately $7,009,711.44. This trade represents a 4.11% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders have sold 45,000 shares of company stock worth $988,650 in the last 90 days. Company insiders own 3.60% of the company's stock.

Institutional Investors Weigh In On Kestra Medical Technologies

Hedge funds and other institutional investors have recently bought and sold shares of the business. Mirae Asset Global Investments Co. Ltd. acquired a new stake in Kestra Medical Technologies in the third quarter valued at $562,000. Police & Firemen s Retirement System of New Jersey lifted its holdings in Kestra Medical Technologies by 34.6% in the fourth quarter. Police & Firemen s Retirement System of New Jersey now owns 5,420 shares of the company's stock valued at $144,000 after acquiring an additional 1,392 shares during the period. Daiwa Securities Group Inc. acquired a new stake in Kestra Medical Technologies in the fourth quarter valued at $72,000. Russell Investments Group Ltd. lifted its holdings in Kestra Medical Technologies by 43.5% in the fourth quarter. Russell Investments Group Ltd. now owns 1,563 shares of the company's stock valued at $41,000 after acquiring an additional 474 shares during the period. Finally, Summit Partners Public Asset Management LLC acquired a new stake in Kestra Medical Technologies in the fourth quarter valued at $9,282,000.

Kestra Medical Technologies Company Profile

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.